ANT-FINANCIAL
15.1.2020 09:52:04 CET | Business Wire | Press release
Ant Financial, operator of the world’s largest payment and lifestyle platform Alipay, today announced the launch of the INCLUSION Fintech Conference, an event that aims to bring together the global financial and technology community, to envision the future of a world that’s more inclusive, green, and sustainable through digital technology.
The inaugural conference, organized by Alipay and Ant Financial together with Alibaba Group, will be held from April 23 to 25, 2020 in Shanghai, a thriving global financial and technology hub. The first INCLUSION event is set to welcome an estimated 20,000 to 30,000 attendees from across the world, making it one of the largest fintech conferences globally.
Participants will hear from and interact with notable speakers including top entrepreneurs, economists, and thought leaders from organizations ranging from financial institutions, technology companies, to research institutions. Speakers will address fundamental questions that will impact the future of the world, such as how to make finance more inclusive, commerce more diversified, and urban lives more efficient.
“Ant Financial is thrilled to host the inaugural INCLUSION Fintech Conference in Shanghai,” said Douglas Feagin, Ant Financial President of International Business Group. “With the launch of the INCLUSION Fintech Conference, we hope to create connections that encourage robust discussion on how technology innovations such as blockchain, Internet of Things and artificial intelligence can propel sustainable development in finance, commerce and the environment. This should promote greater collaboration across the global economy.”
Located near the historic The Bund district, the three-day event will feature more than 100 forums, with keynotes and panels covering major themes such as the global digital economy, digital finance, innovative technology, commerce and cities, and sustainability. Alongside the forums, exhibition areas and special zones will be set up to showcase the latest fintech innovations and digital lifestyle trends.
Ant Financial expects to expand the INCLUSION Fintech Conference series to other global fintech hubs in regions including Europe and Southeast Asia. More information including venue and ticketing details will be made available at www.inclusionconf.com/en .
About the INCLUSION Fintech Conference
The INCLUSION Fintech Conference was officially launched in 2020 to bring together the global financial and technology communities, to envision a world that’s more inclusive, green, and sustainable through digital technology. The inaugural three-day conference in Shanghai, to be held in April 2020, is expected to attract up to 30,000 participants, and will feature more 100 forums, with keynotes and panels covering major themes such as the global digital economy, digital finance, innovative technology, and sustainability.
About Ant Financial
Ant Financial Services Group, officially established in October 2014, is an innovative technology provider that aims to bring inclusive financial services to the world. Headquartered in Hangzhou, China, we are the operator of Alipay, an online payment service launched in 2004 which has since evolved into the world’s largest payment and lifestyle platform.
As a member of the Alibaba digital economy, Ant Financial is working hand in hand with Alibaba Group to make it easy to do business anywhere across the world. Through our innovative technologies, Ant Financial is committed to helping global consumers and small-and-micro enterprises gain access to inclusive financial services that are secure, green, and sustainable, creating greater value for society and bringing equal opportunities to the world.
For more information on Ant Financial, please visit our website at www.antfin.com or follow us on Twitter @AntFinancial and @Alipay.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200115005313/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom